Horizon Pharma PLC (HZNP) Sets New 52-Week Low After Earnings Miss

With 384,400 avg volume, 6 days are for Virtusa Corporation (NASDAQ:VRTU)'s short sellers to cover VRTU's short positions. The SI to Norwood Financial Corporation's float is 0.13%. The average 1 year target price among brokers that have issued a report on the stock in the last year is $21.09. About shares traded. Virtusa Corporation (NASDAQ:VRTU) has declined 13.10% since May 26, 2016 and is downtrending.

Beach Point Capital Management Lp decreased Horizon Pharma Plc (HZNP) stake by 81.63% reported in 2016Q4 SEC filing.

TRADEMARK VIOLATION NOTICE: "Horizon Pharma PLC (HZNP) Sets New 52-Week Low After Earnings Miss" was reported by The Cerbat Gem and is owned by of The Cerbat Gem. The Reaves W H & Company Inc holds 688,858 shares with $28.67 million value, up from 485,858 last quarter. The SI to Horizon Pharma Plc Ord Ireland's float is 8.94%. (NASDAQ:AMD) traded at a yearly high level of $15.55 during the last trading session. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has "Neutral" rating given on Friday, December 9 by Mizuho. It has underperformed by 45.13% the S&P500. Blue Bell Private Wealth Management Llc acquired 60,833 shares as General American Investors (GAM)'s stock rose 1.35%. It also reduced Visa Inc (NYSE:V) stake by 80,363 shares and now owns 2.89M shares. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) was reduced too.

Bale: Madrid should party in Cardiff if…
Ten of thousands of fans are descending on the Welsh capital for the match, with limited hotel capacity to accommodate them. Every time we've had the chance to fight for a trophy, we've done that. "Perhaps we not strongly motivated", Allegri said.

Investors sentiment increased to 1.83 in Q4 2016. Its down 0.44, from 1.46 in 2016Q3. Horizon Pharma PLC had a positive return on equity of 22.73% and a negative net margin of 1.34%. Consonance Capital Management LP acquired a new stake in shares of Horizon Pharma PLC during the third quarter valued at approximately $67,061,000. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by $0.04.

Historically, if we have a peek at price target revisions, Horizon Pharma PLC (NASDAQ:HZNP)'s price target was revised by the analysts two weeks back on 05/09/17 to set its target price at $19.33 where its twelve month high target price was set at $42 and low at $10 while demonstrating the standard deviation of 11.71. Teacher Retirement Sys Of Texas holds 11,475 shares.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, May 8th. Systematic Mgmt Limited Partnership reported 218,495 shares. 240.61 million shares or 0.20% less from 241.09 million shares in 2016Q3 were reported. Deerfield Management Co. increased its stake in shares of Horizon Pharma PLC by 39.2% in the fourth quarter. Sg Americas Lc holds 52,353 shares or 0.02% of its portfolio. Deutsche Bancorporation Ag owns 1,230 shares for 0% of their portfolio. Capital Fund Mgmt holds 291,939 shares or 0.04% of its portfolio.

Fresh CCTV images of Manchester bomber released in bid to track movements
The singer is to return to Manchester on Sunday alongside artists including Coldplay, Justin Bieber and Take That. A British counterterrorism official told CNN it was not clear whether Abedi received training with ISIS in Syria.

Moreover, Mirae Asset Glob Invs Com Limited has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP). Brandywine Global Inv Management Ltd Co invested in 0.26% or 2.49 million shares. Amer National Co Tx invested 0.14% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). 101,900 were accumulated by Parkwood Ltd. Finally, BMO Capital Markets reiterated a "buy" rating and set a $17.00 price target (down from $24.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Therefore 56% are positive. Guggenheim assumed coverage on shares of Horizon Pharma PLC in a research note on Monday, February 27th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The firm has "Neutral" rating by Citigroup given on Wednesday, January 6. The company was initiated on Monday, June 6 by Goldman Sachs. Mizuho cut Horizon Pharma PLC from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $22.00 to $10.00 in a report on Tuesday, May 9th. As per Tuesday, August 9, the company rating was maintained by Citigroup. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $23.44. As per Tuesday, November 8, the company rating was maintained by Mizuho.

Since January 1, 0001, it had 1 insider buy, and 4 selling transactions for $1.32 million activity. Mizuho restated a "buy" rating and set a $25.00 price target on shares of Horizon Pharma PLC in a research note on Wednesday, February 22nd.

In other news, Director Michael G. Grey purchased 10,000 shares of the business's stock in a transaction on Wednesday, May 10th. He performs analysis of Companies and publicizes important information for investor/traders community. The stock's market cap is $1.66 billion. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. SunTrust has "Neutral" rating and $40 target. Barclays Capital maintained it with "Equal-Weight" rating and $43 target in Friday, March 18 report. The company was maintained on Monday, October 31 by Mizuho. (NASDAQ:FFIV) on Friday, February 10. The company was maintained on Wednesday, July 29 by Needham. They issued a "buy" rating and a $30.00 price objective for the company.

French Open 2017: Rafael Nadal seals victory as Robin Haase double faults
The 30-year-old Nadal extended his 2017 clay-court record to 18-1 and his career Roland Garros record to 73-2. Nikoloz Basilashvili is coming off a straight sets win over Viktor Troicki that took 39 games to decide.

Related news